Background {#Sec1}
==========

Malignant fibrous neoplasms (MFN) are very rare malignant tumours of long bones. These tumours include fibrosarcoma, fibromyxosarcoma, periosteal fibrosarcoma and malignant fibrous histiocytoma (MFH) according to classification from the SEER database. Malignant fibrous neoplasms most commonly arise from the extremities \[[@CR1]\], occasionally from the nasal cavity and paranasal sinuses \[[@CR2]\], and rarely from long bone.

MFH was first described by O'Brien in 1963 \[[@CR3]\] and by Kauffman and Stout (Histiocytic tumors (fibrous xanthoma and histiocytoma) in children in 1961 \[[@CR4]\]. It was the most common soft tissue sarcoma \[[@CR5]\]. Fibrosarcoma of long bone (LBFS) is another neoplasm in this region that exhibits nonspecific symptoms such as pain. The final diagnosis of this tumour is based on histopathology and immunohistochemistry \[[@CR6]\].

Malignant tumours of the long bones are challenging with regard to improving patient survival \[[@CR7]\]. Few studies have reported the complications associated with surgical resection. Therefore, it remains unresolved whether a uniform treatment strategy could be beneficial to all patients.

Here, we present an epidemiologic analysis of MFN of long bone using the U.S. National Cancer Institute's SEER database from 1973 to 2015. No previous study has specifically performed an in-depth analysis of cases with MFN of long bones using the database. We analysed 237 cases of MFN of long bones from 18 SEER registries, representing the largest cohort of patients with MFN of long bones studied to date. Our analysis includes demographic and clinicopathologic features of this rare neoplasm, along with its survival outcomes.

Materials and methods {#Sec2}
=====================

Frequency and survival data were obtained from the SEER 18 dataset from 1973 to 2015. SEER had considerably fewer participating registries in the early years, and the number gradually increased relatively recently to reach 18. The cases included in this dataset were diagnosed between 1973 and 2015. Fibrosarcoma cases were screened using the morphological codes for fibrosarcoma (8810/3), fibromyxosarcoma (8811/3), periosteal fibrosarcoma (8812/3), and malignant fibrous histiocytoma (8830/3). Based on the topographical codes, cases with MFN were restricted to the long bone, namely, the long bones of the upper limb, scapula, and associated joints (C40.0), as well as the long bone of the lower limb and associated joints (C40.2).

Frequency data were stratified and analysed by age, gender, race, grade, tumour size, SEER extent of disease, and treatment strategy. SEER extent of disease is categorized into localized, regional, and distant disease. Localized tumour, regional tumour and distant disease are defined as previously reported \[[@CR8]--[@CR11]\]. Five-year survival rates were calculated using Kaplan-Meier analysis, calculating overall survival (OS) and calculating disease-specific survival (CSS) rates \[[@CR12]\]. SEER\*Stat 8.1.5 software (National Cancer Institute, Bethesda, MD) and Microsoft Excel 2013 (Microsoft Corp., Redmond, WA) were used to process the data. Statistical Product and Service Solutions (SPSS) 24th edition was used to yield Kaplan-Meier curves and CSS rates. Probability values (*p* values) *\<* 0.05 were considered statistically significant for all tests.

Results {#Sec3}
=======

The demographic characteristics of the 237 patients with MFN of the long bones identified in the SEER database are displayed in Table [1](#Tab1){ref-type="table"}. The specific histopathological diagnosis was fibrosarcoma (21.5%), fibromyxosarcoma (1.7%), periosteal fibrosarcoma (5.1%), and malignant fibrous histiocytoma (71.7%). Table 1Clinical characteristics of patients with MFN of long bonesVariablesNumber (%)Fibrosarcoma (NOS) *N* = 51Fibromyxosarcoma *N* = 4Periosteal fibrosarcoma *N* = 12Malignant fibrous histiocytoma *N* = 170Total5761485656Age≤161 (2.0%)0 (0%)2 (16.7%)9 (5.3%)12 (5.1%)17--3911 (21.6%)1 (25.0%)2 (16.7%)28 (16.5%)42 (17.7%)40--6016 (31.4%)0 (0.0%)3 (25.0%)54 (31.8%)73 (30.8%)\>6023 (45.1%)3 (75.0%)5 (41.7%)79 (46.5%)110 (46.4%)Race recodeOther4 (7.8%)0 (0.0%)3 (25.0%)9 (5.3%)16 (6.8%)White39 (76.5%)4 (100.0%)9 (75.0%)143 (84.1%)195 (82.3%)Black8 (15.7%)0 (0.0%)0 (0.0%)18 (10.6%)26 (11.0%)SexFemale19 (37.3%)2 (50.0%)6 (50.0%)82 (48.2%)109 (46.0%)Male32 (62.7%)2 (50.0%)6 (50.0%)88 (51.8%)128 (54.0%)Decade of diagnosis1970s8 (15.7%)0 (0.0%)7 (58.3%)7 (4.1%)22 (9.3%)1980s7 (13.7%)0 (0.0%)3 (25.0%)30 (17.6%)40 (16.9%)1990s6 (11.8%)0 (0.0%)0 (0.0%)38 (22.4%)44 (18.6%)2000s17 (33.3%)3 (75.0%)1 (8.3%)73 (42.9%)94 (39.7%)2010s13 (25.5%)1 (25.0%)1 (8.3%)22 (12.9%)37 (15.6%)Tumor gradeUnknown7 (13.7%)1 (25.0%)6 (50.0%)63 (37.1%)77 (32.5%)Low18 (35.3%)1 (25.0%)3 (25.0%)7 (4.1%)29 (12.2%)High26 (51.0%)2 (50.0%)3 (25.0%)100 (58.8%)131 (55.3%)Tumor Size\<5 cm27 (52.9%)0 (0.0%)9 (75.0%)83 (48.8%)119 (50.2%)5 cm-108 (15.7%)0 (0.0%)0 (0.0%)18 (10.6%)26 (11.0%)\>1013 (25.5%)4 (100.0%)2 (16.7%)42 (24.7%)61 (25.7%)Unknown3 (5.9%)0 (0.0%)1 (8.3%)27 (15.9%)31 (13.1%)StageUnknown4 (7.8%)0 (0.0%)1 (8.3%)11 (6.5%)16 (6.8%)Local23 (45.1%)2 (50.0%)4 (33.3%)62 (36.5%)91 (38.4%)Region16 (31.4%)1 (25.0%)5 (41.7%)62 (36.5%)84 (35.4%)distant8 (15.7%)1 (25.0%)2 (16.7%)35 (20.6%)46 (19.4%)SurgeryNo13 (19.4%)0 (0.0%)5 (41.7%)38 (22.4%)56 (23.6%)Yes38 (74.5%)4 (100.0%)7 (58.3%)131 (77.1%)180 (75.9%)Unknown0 (0.0%)0 (0.0%)0 (0.0%)1 (0.6%)1 (0.4%)RadiotherapyNo/Unknown36 (70.6%)4 (100.0%)8 (66.7%)133 (78.2%)181 (76.4%)Yes15 (29.4%)0 (0.0%)4 (33.3%)37 (21.8%)56 (23.6%)ChemotherapyNo/Unknown36 (70.6%)3 (75.0%)8 (66.7%)87 (51.2%)134 (56.5%)Yes15 (29.4%)1 (25.0%)4 (33.3%)83 (48.8%)103 (43.5%)DeadNo15 (29.4%)3 (75.0%)3 (25.0%)56 (32.9%)77 (32.5%)Yes36 (70.6%)1 (25.0%)9 (75.0%)114 (67.1%)160 (67.5%)Tumor sequenceFirst39 (76.5%)4 (100.0%)12 (100.0%)153 (90.0%)208 (87.8%)≥Second12 (23.5%)0 (0.0%)0 (0.0%)17 (10.0%)29 (12.2%)5-year OS rate31.40%50.00%58.30%40.60%39.70%5-year CSS rate62.70%75.00%66.70%58.80%60.30%10-year OS rate11.80%50.00%50.00%23.50%22.80%10-year CSS rate58.80%75.00%58.30%55.30%56.50%*Abbreviations*: *CSS* Cancer-specific survival, *OS* Overall survival, *MFN* Malignant fibrous neoplasms

Histologically, 55.3% of cases were high grade, 12.2% were low grade, and 32.5% were an unknown tumour grade. More than half (50.2%) of the tumours were at less than 5 cm in size. The extent of disease showed that the majority presented with locally invasive disease (38.4%). Forty-six patients (19.4%) had developed metastasis at presentation. Most patients were diagnosed first with malignant primary tumours (87.8%). After diagnosis, 75.9% of patients underwent surgical treatment and 56.5% of the patients underwent chemotherapy. A total of 160 patients (67.5%) died. The OS rates of the entire cohort at 5 and 10 years were 39.7 and 22.8%, respectively. The CSS rates at 5 and 10 years were 60.3 and 56.5%, respectively.

The 5- and 10-year OS rates for patients with fibrosarcoma of long bones were 31.4 and 11.8%, respectively, and the respective 5- and 10-year CSS rates were 62.7 and 58.8%. For patients with malignant fibrous histiocytoma of long bones, the OS rates were 40.6 and 23.5% and the CSS rates were 58.8 and 55.3%, respectively (Table [1](#Tab1){ref-type="table"}).

Univariate and multivariate analysis of parameters that influence overall survival (OS) and cancer-specific survival (CSS) are illustrated in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Table 2Univariate and multivariate analyses for OS for patients identified in the SEER Program database from 1973 to 2015VariablesUnivariate analysisMultivariate analysis*p*-valueHazard ratio (95% CI)*p*-valueHazard ratio (95% CI)Age≤16/1/117--390.1242.5620.0982.765 (0.827--9.243)40--600.037\*3.47 (1.075--11.202)0.027\*3.81 (1.163--12.486)\>600.001\*7.381 (2.323--23.45)0.004\*5.688 (1.722--18.782)SexMale/1Female0.2760.840 (0.613--1.150)Decade of diagnosis1970s/11980s0.9380.977 (0.552--1.731)1990s0.2041.444 (0.819--2.545)2000s0.3820.784 (0.454--1.353)2010s0.9991 (0.512--1.954)Race recodeOther/1White0.4351.293 (0.679--2.462)Black0.5051.301 (0.6--2.822)Tumor GradeLow/1High0.0651.691 (0.968--2.954)Unknown0.02\*1.97 (1.115--3.48)Tumor typeFibrosarcoma (NOS)/1Fibromyxosarcoma0.1880.263 (0.036--1.923)Periosteal fibrosarcoma0.2490.649 (0.311--1.354)Malignant fibrous histiocytoma0.6090.906 (0.621--1.322)Tumor Size\<5 cm/1/15 cm-100.1091.889 (0.868--4.114)0.034\*2.335 (1.065--5.124)\>10\< 0.001\*4.714 (2.111--10.527)0.001\*4.051 (1.769--9.275)Unknown\< 0.001\*3.301 (1.602--6.801)0.027\*2.324 (1.1--4.91)Tumor sequenceFirst/1/1≥Second0.031\*1.618 (1.045--2.505)0.1421.425 (0.889--2.287)StageLocal/1/1region0.1281.355 (0.916--2.004)0.0911.421 (0.945--2.135)distant\< 0.001\*5.383 (3.517--8.237)\< 0.001\*3.917 (2.427--6.321)unknown\< 0.001\*2.68 (1.468--4.892)0.5151.239 (0.65--2.359)SurgeryNo/1/1Yes\< 0.001\*0.267 (0.19--0.376)\< 0.001\*0.397 (0.262--0.6)unknown0.4080.433 (0.06--3.144)0.5280.515 (0.066--4.05)Radiotherapyno/unknown/1/1Yes0.003\*1.684 (1.196--2.371)0.8310.959 (0.655--1.404)Chemotherapyno/unknown/1/1Yes0.023\*0.688 (0.499--0.949)0.2820.816 (0.563--1.182)*Abbreviations*: *OS* Overall survival, *SEER* Surveillance, epidemiology, and end results\**p* \< 0.05 Table 3Univariate and multivariate analyses for CSS for patients identified in the SEER Program database from 1973 to 2015VariablesUnivariate analysisMultivariate analysis*p*-valueHazard ratio (95% CI)*p*-valueHazard ratio (95% CI)Age≤16/1/117--390.1922.243 (0.666--7.554)0.12.803 (0.822--9.556)40--600.2062.153 (0.655--7.074)0.1832.271 (0.679--7.601)\>600.032\*3.569 (1.112--11.454)0.03\*3.863 (1.14--13.091)SexMale/1Female0.4270.854 (0.578--1.261)Decade of diagnosis1970s/11980s0.821.088 (0.526--2.249)1990s0.4471.323 (0.643--2.72)2000s0.3580.726 (0.367--1.437)2010s0.5140.755 (0.324--1.759)Race recodeOther/1White0.8531.076 (0.497--2.329)Black0.281.633 (0.671--3.974)Tumor GradeHigh/1Low0.1011.859 (0.885--3.905)Unknown0.062.079 (0.969--4.464)Tumor typeFibrosarcoma (NOS)/1Fibromyxosarcoma0.4360.45 (0.061--3.351)Periosteal fibrosarcoma0.5710.754 (0.284--2.004)Malignant fibrous histiocytoma0.8641.043 (0.643--1.693)Tumor Size\<5 cm/1/15 cm-100.1631.446 (0.861--2.426)0.2051.908 (0.703--5.176)\>10\< 0.001\*7.595 (4.553--12.671)0.033\*3.075 (1.092--8.659)Unknown0.082.108 (0.914--4.863)0.0822.314 (0.899--5.951)Tumor sequenceFirst/1/1≥Second0.023\*0.042 (0.003--0.641)0.9430Stagelocal/1/1region0.1281.355 (0.916--2.004)0.1451.481 (0.873--2.514)distant\< 0.001\*5.383 (3.517--8.237)\< 0.001\*4.401 (2.47--7.841)unknown\< 0.001\*2.68 (1.468--4.892)0.9420.967 (0.396--2.363)SurgeryNo/1/1Yes\< 0.001\*0.226 (0.15--0.34)\< 0.001\*0.318 (0.191--0.527)unknown0.96300.9890Radiotherapyno/unknown/1/1Yes0.02\*1.652 (1.084--2.517)0.5890.878 (0.546--1.409)Chemotherapyno/unkown/1/1yes0.4810.87 (0.59--1.282)0.8710.963 (0.609--1.523)*Abbreviations*: *CSS* Cancer-specific survival, *SEER* Surveillance, epidemiology, and end results\**p* \< 0.05

For both OS and CSS, race, gender, decade of diagnosis and tumour type showed no significant effect on survival (*p* \> 0.05; Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Univariate survival analysis revealed that older age (age \> 60 years) was significantly associated with a worse OS (HR = 7.381, *p* = 0.001; Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}a) and CSS (HR = 3.569, *p* = 0.032; Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}a). Tumour size (\> 10 cm) was significantly associated with a worse OS (HR = 4.714, *p* \< 0.001; Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}e) and CSS (HR = 7.595, *p* \< 0.001; Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}e). Tumour sequence (second) was significantly associated with a worse OS (HR = 1.618, *p* = 0.031; Table [2](#Tab2){ref-type="table"}) but a higher CSS (HR = 0.042, *p* = 0.023; Table [3](#Tab3){ref-type="table"}). The stage (distant) was significantly associated with a worse OS (HR = 5.383, *p* \< 0.001; Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}f) and CSS (HR = 5.383, *p* \< 0.001; Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}f). Radiotherapy was significantly associated with a worse OS (HR = 1.684, *p* = 0.003; Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}d) and CSS (HR = 1.652, *p* = 0.02; Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}d). Surgery was significantly associated with a better OS (HR = 0.267, *p* \< 0.001; Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}b) and CSS ((HR = 0.267, *p* = 0.226; Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}b). Chemotherapy was significantly associated with a better OS (HR = 0.688, *p* = 0.023; Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}c) but not with CSS (HR = 0.226, *p* \< 0.001; Table [3](#Tab3){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}c). Fig. 1Kaplan--Meier method estimated OS in patients with MFN of the long bones stratified by **a** age at diagnosis (years), **b** surgery, **c** chemotherapy or not, **d** radiation treatment, **e** tumour size, **f** stage, **g** tumor sequence. Abbreviations: OS, overall survival; MFN, malignant fibrous neoplasms Fig. 2Kaplan--Meier method estimated CSS in patients with MFN of the long bones stratified by **a** age at diagnosis (years), **b** surgery, **c** chemotherapy or not, **d** radiation treatment, **e** tumour size, **f** stage. Abbreviations: CS, cancer-specific survival; MFN, malignant fibrous neoplasms

Upon multivariate analysis of all patients (Table [2](#Tab2){ref-type="table"}), age (\> 60 years vs \< 16 years, HR = 5.688; *p* = 0.004; 40--60 years vs \< 16 years, HR = 3.81; *p* = 0.027), stage (distant vs. localized, HR = 3.917, *p* \< 0.001), tumour size (\> 10 cm vs \< 5 cm, HR = 4.051; *p* = 0.001; 5--10 cm vs \< 5 cm, HR = 2.335; *p* = 0.034), and surgery (HR = 0.397; *p* \< 0.001) were independent predictors of OS.

The results of the multivariate analysis of the parameters that influence CSS are presented in Table [3](#Tab3){ref-type="table"}. Age (\> 60 years vs \< 16 years, HR = 3.863; 95% CI, 1.14--13.091; *p* = 0.03), stage (distant vs. localized, HR = 4.401, 95% CI, 2.47--7.841, *p* \< 0.001), tumour size (\> 10 cm vs \< 5 cm, HR = 3.075; 95% CI, 1.092--8.659; *p* = 0.033; 5--10 cm vs \< 5 cm, HR = 2.335; 95% CI, 1.065--5.124; *p* = 0.034), and surgery (HR = 0.318; 95% CI, 0.191--0.527; *p* \< 0.001) were independent predictors of CSS.

Discussion {#Sec4}
==========

MFN are rare malignant tumours. Attention was paid to fibrosarcoma, fibromyxosarcoma, periosteal fibrosarcoma and malignant fibrous histiocytoma.

These tumours can infiltrate adjacent tissues and metastasize distally \[[@CR13]--[@CR19]\]. However, the outcome and prognosis of patients with MFN of long bones have not been reported because of its rarity. To our knowledge, the current study is the first to report the prognostic factors that affect the survival of patients with MFN of long bones using multivariate regression analysis.

In the current study, we identified 237 cases of malignant fibrous neoplasms of long bone based on the SEER database from 1973 to 2015. The OS and CSS rates at 5 years were 39.7 and 60.3%, respectively, while the previous study results showed that the OS and CSS of sinonasal fibrosarcoma were 71.7 and 77.8%, respectively \[[@CR13]\].

Although malignant fibrous histiocytoma (MFH) ceased to be recognised as an entity in the 2013 edition of the WHO classification of bone and soft tissue tumours \[[@CR20]\], undifferentiated high-grade pleomorphic sarcoma is listed as a new synonym for MFH of bone, still with the same code 8830/3, in the recently published ICD-O-3.2. However, the registrations of undifferentiated high-grade pleomorphic sarcoma of bone still decreased in the seer database. This might explain the recent decrease in registrations of MFH. Therefore, this study was of more than purely historical interest.

Survival by age {#Sec5}
---------------

We observed different survival rates by age at diagnosis in many studies \[[@CR14]\]. In contrast, we found a higher risk of poor OS in the elder group. In the multivariate analysis of OS for patients aged 17--39 years the HR was 2.765 (*P* = 0.098), for those aged 40--60 years the HR was 3.81 (*P* = 0.027), and for those aged \> 60 years the HR was 5.688 (*P* = 0.004). We also found a higher risk of poor CSS in the elder group. In the multivariate analysis of CSS for those aged \> 60 years, the HR was 3.863 (*P* = 0.03\*).

Survival by gender, race and decade of diagnosis {#Sec6}
------------------------------------------------

Our results were consistent with previous results where no differences in survival by gender, or race but not decades were founded \[[@CR21]\]. The differences of decades might be caused by the primary site of long bone or small bone.

Survival by radiotherapy and chemotherapy {#Sec7}
-----------------------------------------

Radiotherapy was used as an adjunct to surgical management in patients with positive margins \[[@CR22]\]. In the univariate analysis of OS, radiotherapy (RT) was associated with poor CSS (HR was 1.652(*P* = 0.02)) and OS (HR was 1.684(*P* = 0.003)). The results were consistent with a recent study \[[@CR15]\]. This may be caused by the selection bias of patients with radiotherapy. Chemotherapy was also an important adjuvant therapy. In the multivariate analysis of OS and CSS, we did not find that chemotherapy was an independent prognostic factor for OS and CSS. However, a previous study demonstrated that clinical factors were associated with radiotherapy only in nonmetastatic malignant fibrous histiocytoma (MFH) of soft tissues \[[@CR1]\].

Survival for tumour type and tumour sequence {#Sec8}
--------------------------------------------

Tumour type was not an independent prognostic indicator for OS or CSS in multivariate analysis. In addition, tumour sequence was an independent prognostic indicator of OS and CSS, suggesting that patients with second primary bone MFN in their long bones may have a worse prognosis than those with a first primary tumour. The patients' number of more than 2 sequence was as low as 29, among which 12 in fibrosarcoma, 17 in malignant fibrous histiocytoma. This leads to the difficulty in analyzing in multivariate analysis. Therefore, the results of tumour sequence should be taken into consideration carefully.

Survival by tumour size {#Sec9}
-----------------------

For smaller tumours with no evidence of metastasis, surgical extirpation alone may be the definitive treatment \[[@CR16], [@CR23]\]. Our study showed that tumour size \> 10 cm was a prognostic factor for both poor OS and CSS, which was consistent with a recent study \[[@CR16]\].

Survival for stage and surgery {#Sec10}
------------------------------

Stage and surgery have been previously recognized as predictors of survival in patients with malignant bone tumours \[[@CR24]--[@CR26]\]. These factors were also independent predictors of OS and CSS in the study. MFN was highly metastatic tumour. Therefore, surgical removal of the primary tumour and distant lesions should be addressed and may be applicable to prolong survival in patients with MFN of the long bones and metastasis at diagnosis. Surgery remains the primary treatment strategy for MFN. Patients treated with this strategy had the best OS and CSS. Finally, there was not significant difference between upper limbs and lower limbs (data not shown).

Strengths and limitations {#Sec11}
-------------------------

This study is a population-based, with high-quality data, and the largest ever published on this category of rare tumours. However, this study has several limitations. These include the fact that there were no data on surgical type, node status, and RT dose.

Conclusion {#Sec12}
==========

This is the largest population-based study to show demographics and analyse the prognosis of patients with MFN of the long bones. Independent predictors of OS included age, stage, tumour size and surgery. Age, stage, tumour size and surgery were also independent predictors of CSS. The results of this study may improve doctors' understanding of the features and outcomes of MFN of the long bones. It may also be useful for patient health education and to provide a foundation for future research.
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